{[ promptMessage ]}

Bookmark it

{[ promptMessage ]}

abtacquisitionofsolvaypharmceuticals092809-091005083933-phpapp02

Abtacquisitionofsolvaypharmceuticals092809-091005083933-phpapp02

Info icon This preview shows pages 1–4. Sign up to view the full content.

View Full Document Right Arrow Icon
GDS_70000_Title_v1 1 Abbott’s Acquisition of Solvay Pharmaceuticals
Image of page 1

Info icon This preview has intentionally blurred sections. Sign up to view the full version.

View Full Document Right Arrow Icon
2 GDS_70000_Title_v1 2 Acquisition of Solvay Pharmaceuticals for €4.5 Billion Supports Abbott’s Long-Term Growth Strategy Abbott Strategy Solvay Brings Adds >$3B in annual long-term product revenue 75% OUS revenue; 70% branded generics Complementary product portfolio in cardiology, neuroscience and gastroenterology Adds a growing global vaccines business and modest molecular diagnostics business Solvay infrastructure is platform for expansion Significant presence in emerging markets, including Eastern Europe and Asia Strong brand recognition >$500MM in incremental R&D investment capacity, adding a mix of late- and early-stage assets Provides Abbott opportunity to accelerate near- and long-term pharmaceutical growth ~$0.10 accretive to ongoing EPS in 2010 Ramping up to more than $0.20 accretion by 2012 Ongoing EPS accretion increases after 2012 Expand presence in high- growth emerging markets
Image of page 2